Literature DB >> 24880939

State of melanoma: an historic overview of a field in transition.

Vikram C Gorantla1, John M Kirkwood2.   

Abstract

The last 30 years has seen a revolution in melanoma. Fundamental elements of the surgical, adjuvant medical, and systemic therapy for the disease have been significantly altered toward improved management and better outcomes. The intent of this article is to reflect on past efforts and research in melanoma and the current landscape of treatment of melanoma. The authors also hope to capture the excitement currently rippling through the field and the hope for a cure. The intent of treatment of advanced melanoma, which was once considered incurable, has changed from palliative to potentially curative.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant; Biology; Combination therapy; Immunotherapy; Melanoma; Neoadjuvant; Prognosis; Targeted therapies

Mesh:

Year:  2014        PMID: 24880939      PMCID: PMC4040458          DOI: 10.1016/j.hoc.2014.02.010

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  117 in total

1.  Spontaneous regression of human melanoma: clinical and experimental studies.

Authors:  W C SUMNER; A G FORAKER
Journal:  Cancer       Date:  1960 Jan-Feb       Impact factor: 6.860

Review 2.  Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.

Authors:  Donald L Morton
Journal:  Clin Exp Metastasis       Date:  2012-06-24       Impact factor: 5.150

3.  The impact of shave biopsy on the management of patients with thin melanomas.

Authors:  Michael Lowe; Nikki Hill; Andrew Page; Suephy Chen; Keith A Delman
Journal:  Am Surg       Date:  2011-08       Impact factor: 0.688

4.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Authors:  Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

Review 5.  Genetic alterations in signaling pathways in melanoma.

Authors:  Frank G Haluska; Hensin Tsao; Helen Wu; Frank S Haluska; Alexander Lazar; Vikas Goel
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

6.  Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes.

Authors:  Nabil Wasif; Sanjay P Bagaria; Partha Ray; Donald L Morton
Journal:  J Surg Oncol       Date:  2011-03-04       Impact factor: 3.454

7.  Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.

Authors:  K A Margolin; J H Doroshow; S A Akman; L A Leong; R J Morgan; G Somlo; J Raschko; C Pereira; L Yonemoto; C Ahn
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544

8.  Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.

Authors:  Dimitrios Pectasides; Urania Dafni; Dimitrios Bafaloukos; Dimosthenis Skarlos; Aristidis Polyzos; Dimosthenis Tsoutsos; Haralambos Kalofonos; George Fountzilas; Petros Panagiotou; George Kokkalis; Othon Papadopoulos; Ourania Castana; Stefanos Papadopoulos; Elias Stavrinidis; Georgia Vourli; John Ioannovich; Helen Gogas
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

9.  Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma.

Authors:  D E Elder; L I Goldman; S C Goldman; M H Greene; W H Clark
Journal:  Cancer       Date:  1980-10-15       Impact factor: 6.860

10.  Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Authors:  Ahmad A Tarhini; Howard Edington; Lisa H Butterfield; Yan Lin; Yongli Shuai; Hussein Tawbi; Cindy Sander; Yan Yin; Matthew Holtzman; Jonas Johnson; Uma N M Rao; John M Kirkwood
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more
  13 in total

Review 1.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 2.  Targeting immune checkpoints in melanoma: an update.

Authors:  Rodrigo R Munhoz; Alejandro Falcón González; Vanessa A Reed; Michael A Postow
Journal:  Melanoma Manag       Date:  2015-11-24

3.  Clinical significance of prognostic nutritional index (PNI) in malignant melanoma.

Authors:  Cem Mirili; Ali Yılmaz; Serkan Demirkan; Mehmet Bilici; Salim Basol Tekin
Journal:  Int J Clin Oncol       Date:  2019-05-09       Impact factor: 3.402

4.  Management of the positive sentinel lymph node in the post-MSLT-II era.

Authors:  Brooke C Bredbeck; Eman Mubarak; Daniela G Zubieta; Rachael Tesorero; Adam R Holmes; Lesly A Dossett; Kyle K VanKoevering; Alison B Durham; Tasha M Hughes
Journal:  J Surg Oncol       Date:  2020-09-06       Impact factor: 3.454

5.  Sifting Through It All: Characterizing Melanoma Patients' Utilization of the Internet as an Information Source.

Authors:  Sarah Nicole Hamilton; Elena P Scali; Irene Yu; Eva Gusnowski; Paris-Ann Ingledew
Journal:  J Cancer Educ       Date:  2015-09       Impact factor: 2.037

Review 6.  Detection of cancer metastasis: past, present and future.

Authors:  Catherine Alix-Panabieres; Anthony Magliocco; Luis Enrique Cortes-Hernandez; Zahra Eslami-S; Daniel Franklin; Jane L Messina
Journal:  Clin Exp Metastasis       Date:  2021-05-07       Impact factor: 5.150

Review 7.  Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.

Authors:  Teresa Kim; Rodabe N Amaria; Christine Spencer; Alexandre Reuben; Zachary A Cooper; Jennifer A Wargo
Journal:  Cancer Biol Med       Date:  2014-12       Impact factor: 4.248

8.  Ensemble Modeling Approach Targeting Heterogeneous RNA-Seq data: Application to Melanoma Pseudogenes.

Authors:  Enrico Capobianco; Camilo Valdes; Samanta Sarti; Zhijie Jiang; Laura Poliseno; Nicolas F Tsinoremas
Journal:  Sci Rep       Date:  2017-12-11       Impact factor: 4.379

9.  Evaluation of In Vitro Antioxidant and Anticancer Properties of the Aqueous Extract from the Stem Bark of Stryphnodendron adstringens.

Authors:  Débora da Silva Baldivia; Daniel Ferreira Leite; David Tsuyoshi Hiramatsu de Castro; Jaqueline Ferreira Campos; Uilson Pereira Dos Santos; Edgar Julian Paredes-Gamero; Carlos Alexandre Carollo; Denise Brentan Silva; Kely de Picoli Souza; Edson Lucas Dos Santos
Journal:  Int J Mol Sci       Date:  2018-08-17       Impact factor: 5.923

10.  Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.

Authors:  David A Close; John M Kirkwood; Ronald J Fecek; Walter J Storkus; Paul A Johnston
Journal:  SLAS Discov       Date:  2020-11-18       Impact factor: 3.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.